KaloBios Pharmaceuticals, Inc.' KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients  
10/15/2009 8:23:43 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Phase 1/2 clinical trial results with KB001, a Humaneeredâ„¢, high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients showed an acceptable safety profile as well as trends toward reducing tissue inflammation and clearance of the bacterium. Results of the multi-center, randomized, double-blind, single-dose, placebo-controlled study are being presented today at the North American Cystic Fibrosis Conference in Minneapolis, MN. KaloBios is developing KB001 for the treatment and/or prevention of Pseudomonas aeruginosa infections in both cystic fibrosis patients and intensive care patients on ventilation, for whom Pseudomonas-caused pneumonia is a major costly health care problem.